Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Utilities Select Sector SPDR Fund — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while Utilities Select Sector SPDR Fund trades at $41.15 (market cap $23.28B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.5× Utilities Select Sector SPDR Fund's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Utilities Select Sector SPDR Fund for 80 Days on average.
| VRTX | XLU | |
|---|---|---|
Market Cap | $128.16B | $23.28B |
Volume | 806,603 | 44,925,171 |
Sector | Health | — |
52-Week High | $557.96 | $47.73 |
52-Week Low | $407.37 | $39.25 |
Typical Hold Time | 120 Days | 80 Days |
Enterprise Value | $122.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
XLU, the Utilities Select Sector SPDR ETF, trades at $41.15, down 0.02% on the day, and is near recent lows amid sector-wide pressure from rising interest rates. Technical indicators show a mixed but overall bullish signal, with moving averages bullish and oscillators neutral. The ETF recently hit a 52-week low, reflecting investor concerns over utility stocks as defensive plays in a higher-rate environment. News highlights oversold conditions and debates over AI-driven power demand versus regulatory hurdles.
Outlook remains cautious; while oversold conditions may attract contrarian buyers, persistent rate hikes and regulatory freezes on data centers pose headwinds. The dividend yield offers income, but sector volatility requires careful risk management amid macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
